Ritonavir, with trade name Norvir® (Abbott Laboratories), is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS.

Ritonavir is frequently prescribed as the protease inhibitor component in HAART because it inhibits the same host enzyme that metabolizes NRTIs and NNRTIs. This inhibition leads to higher plasma concentrations of these latter drugs, allowing the clinician to lower their dose and frequency.

History

---

Ritonavir is manufactured as Norvir® by Abbott Laboratories. Research that led to the drug's development was financed in part by a $3,500,000 federal grant through the National Institutes of Health (NIH). The Food and Drug Administration (FDA) approved ritonavir on March 1, 1996, making it the seventh approved antiretroviral drug in the United States. In 2003, Abbott raised the price of a Norvir course from USD $1.71 per day to $8.57 per day, leading to claims of price gouging by patients' groups and some members of Congress. Consumer group Essential Inventions petitioned the NIH to override the Norvir patent, but the NIH announced on August 4, 2004 that it would not invoke its legal right to allow generic production of Norvir, citing potential adverse effects on the pharmaceutical market.

More on [ Ritonavir ]

Ritonavir - Twitter Search

Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir.. http://bit.ly/7NWni4
zampbioworld (zampbioworld) Tue, 22 Dec 2009 20:29:35 -0000
Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir.. http://bit.ly/7NWni4
#pharmacy Occurrence of Selective Ritonavir Nonadherence and Dose-Staggering in Recipients of Boosted HIV-1 Protease .. http://bit.ly/8MpqvJ
bookapharmacist (Kazeem Olalekan) Tue, 22 Dec 2009 15:33:57 -0000
#pharmacy Occurrence of Selective Ritonavir Nonadherence and Dose-Staggering in Recipients of Boosted HIV-1 Protease .. http://bit.ly/8MpqvJ
PedNews: Meds Subscribe to Ritonavir RSS feed